(Q80510509)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15338744%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

review article

1 reference

title

Cyclin-dependent kinases as targets for cancer therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15338744%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

author name string

Manish A Shah

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15338744%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Gary K Schwartz

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15338744%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

publication date

1 January 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15338744%20AND%20SRC:MED&resulttype=core&format=json

Cancer chemotherapy and biological response modifiers

1 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15338744%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15338744%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

page(s)

145-170

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15338744%20AND%20SRC:MED&resulttype=core&format=json

CDK inhibitors: positive and negative regulators of G1-phase progression

1 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Cyclins and cell cycle checkpoints

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Human and yeast cdk-activating kinases (CAKs) display distinct substrate specificities

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

A Restriction Point for Control of Normal Animal Cell Proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

To cycle or not to cycle: a critical decision in cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

The S phase: Beginning, middle, and end: A perspective.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

The DNA damage response: putting checkpoints in perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Involvement of Brca1 in S-phase and G(2)-phase checkpoints after ionizing irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Cancer and the cell cycle

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Spindle assembly and the art of regulating microtubule dynamics by MAPs and Stathmin/Op18.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

The spindle assembly checkpoint

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

How cells get the right chromosomes

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

BIRinging chromosomes through cell division--and survivin' the experience

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

The molecular basis and potential role of survivin in cancer diagnosis and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

A p34(cdc2) survival checkpoint in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Cell cycle control and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Cdk inhibitors in development and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

An antiinflammatory cum immunomodulatory piperidinylbenzopyranone from dysoxylum binectariferum : isolation, structure and total synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

UCN-01 and UCN-02, new selective inhibitors of protein kinase C. II. Purification, physico-chemical properties, structural determination and biological activities

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Calphostin C (UCN-1028C), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase C

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Effect of UCN-01, a selective inhibitor of protein kinase C, on the cell-cycle distribution of human epidermoid carcinoma, A431 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

UCN-01, 7-hydroxyl-staurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

The retinoblastoma gene product is a negative modulator of the apoptotic pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Chemistry and clinical biology of the bryostatins

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Modeling of the bryostatins to the phorbol ester pharmacophore on protein kinase C

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Bryostatin, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic leukemia cells HL-60.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Divergent effects of bryostatin 1 and phorbol myristate acetate on cell cycle arrest and maturation in human myelomonocytic leukemia cells (U937).

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Inhibition of protein kinase C activator-mediated induction of p21CIP1 and p27KIP1 by deoxycytidine analogs in human leukemia cells: relationship to apoptosis and differentiation

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Bryostatin 1, a novel antineoplastic agent and protein kinase C activator, induces human myalgia and muscle metabolic defects: a 31P magnetic resonance spectroscopic study

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

A phase I study of intravenous bryostatin 1 in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

A phase II study of bryostatin 1 in metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Treatment of patients with metastatic melanoma with bryostatin-1--a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Phase II evaluation of bryostatin-1 in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Phase II studies of bryostatin-1 in patients with advanced sarcoma and advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

A model for tumor response to chemotherapy: an integration of the stem cell and somatic mutation hypotheses

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Apoptosis: A Basic Biological Phenomenon with Wideranging Implications in Tissue Kinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Cell death: the significance of apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Dysregulation of apoptosis in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

An evolutionary perspective on apoptosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Mechanisms of apoptosis: integration of genetic, biochemical, and cellular indicators

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Protease activation during apoptosis: death by a thousand cuts?

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Studies of the lamin proteinase reveal multiple parallel biochemical pathways during apoptotic execution

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Apoptosis and cancer drug targeting

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Apoptosis in cancer therapy: crossing the threshold

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Apoptosis. Its significance in cancer and cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Cell death in health and disease: the biology and regulation of apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Implications of apoptotic cell death regulation in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Survival factors, intracellular signal transduction, and the activation of endonucleases in apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

p53-dependent apoptosis modulates the cytotoxicity of anticancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Apoptosis meets signal transduction: elimination of a BAD influence

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Protein kinase C targeting in antineoplastic treatment strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

p53, the cellular gatekeeper for growth and division

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Radiation-induced cell cycle arrest compromised by p21 deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Requirement for p53 and p21 to sustain G2 arrest after DNA damage

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Disruption of p53 in human cancer cells alters the responses to therapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Identification and classification of p53-regulated genes

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Cell-cycle arrest versus cell death in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

THE DEVELOPMENT AND CLINICAL UTILITY OF THE TAXANE CLASS OF ANTIMICROTUBULE CHEMOTHERAPY AGENTS

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Promotion of microtubule assembly in vitro by taxol

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Taxol assembles tubulin in the absence of exogenous guanosine 5'-triphosphate or microtubule-associated proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Taxol stabilizes microtubules in mouse fibroblast cells

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

A phase I trial of taxol given by a 6-hour intravenous infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Accumulation of cyclin B1, activation of cyclin B1-dependent kinase and induction of programmed cell death in human epidermoid carcinoma KB cells treated with taxol.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Temporal and spatial control of cyclin B1 destruction in metaphase

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Phosphorylation of Bcl-2 protein and association with p21Ras in Ras-induced apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Molecular effects of paclitaxel: myths and reality (a critical review).

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Differential Taxol-dependent arrest of transformed and nontransformed cells in the G1 phase of the cell cycle, and specific-related mortality of transformed cells

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Paclitaxel-induced cell death: where the cell cycle and apoptosis come together

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Loss of the bcl-2 phosphorylation loop domain increases resistance of human leukemia cells (U937) to paclitaxel-mediated mitochondrial dysfunction and apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Bcl-xL modulates apoptosis induced by anticancer drugs and delays DEVDase and DNA fragmentation-promoting activities

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Bryostatin 1 enhances paclitaxel-induced mitochondrial dysfunction and apoptosis in human leukemia cells (U937) ectopically expressing Bcl-xL

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Effect of bryostatin 1 on taxol-induced apoptosis and cytotoxicity in human leukemia cells (U937).

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

The current status of camptothecin analogues as antitumor agents

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Topoisomerase I inhibitors: topotecan and irenotecan

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Abrogation of the S phase DNA damage checkpoint results in S phase progression or premature mitosis depending on the concentration of 7-hydroxystaurosporine and the kinetics of Cdc25C activation.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Topoisomerase-I inhibitors for human malignant glioma: differential modulation of p53, p21, bax and bcl-2 expression and of CD95-mediated apoptosis by camptothecin and beta-lapachone.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Clinical trials of irinotecan hydrochloride (CPT, campto injection, topotecin injection) in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Enhancement of camptothecin-induced cytotoxicity with UCN-01 in breast cancer cells: abrogation of S/G(2) arrest

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Apoptotic response to camptothecin and 7-hydroxystaurosporine (UCN-01) in the 8 human breast cancer cell lines of the NCI Anticancer Drug Screen: multifactorial relationships with topoisomerase I, protein kinase C, Bcl-2, p53, MDM-2 and caspase path

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Kinetics and thermodynamics of the interaction of 5-fluoro-2'-deoxyuridylate with thymidylate synthase

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Sequence-dependent antagonism between fluorouracil and paclitaxel in human breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Effect of 5-fluorouracil on cell cycle regulatory proteins in human colon cancer cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Cell-cycle-directed regulation of thymidylate synthase messenger RNA in human diploid fibroblasts stimulated to proliferate

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

DNA damage and cell cycle checkpoints

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Induction of apoptosis by taxol and cisplatin and effect on cell cycle-related proteins in cisplatin-sensitive and -resistant human ovarian cells

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

UCN-01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G(2) checkpoint abrogation

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Cell cycle effects of gemcitabine

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

The role of p53 in gemcitabine-mediated cytotoxicity and radiosensitization.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

Cell cycle perturbations in acute myeloid leukemia samples following in vitro exposures to therapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921007-3

7 January 2021

10.1016/S0921-4410(03)21007-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15338744%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference